ProfileGDS5678 / 1437244_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 80% 84% 82% 80% 85% 85% 78% 82% 84% 87% 83% 87% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0327183
GSM967853U87-EV human glioblastoma xenograft - Control 25.6704380
GSM967854U87-EV human glioblastoma xenograft - Control 36.1704984
GSM967855U87-EV human glioblastoma xenograft - Control 46.0266582
GSM967856U87-EV human glioblastoma xenograft - Control 55.7398580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.186285
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2669685
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3637378
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.891182
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2611684
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7290687
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1805283
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6479787
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2957885